Pharmaceutical & BioScience Society, PBSS

Seminar luncheon

The New EMA Guideline and Evolving Expectations for Patient Safety in First-in-Human Clinical Trials: Keeping the Focus on the Science

Speakers: Michael Rothenberg, MD PhD (Roche / Genentech)
Organizers:
Date: 2018-08-03
Time: 11:00-13:30 Pacific Time
Registration fee: (USD): Food: $0.
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor:
Vendor show vendors registered to date: (7)Alturas Analytics; BUCHI Corporation; Celerion; Covance; KCAS; Sekisui XenoTech, LLC; WORLDWIDE CLINICAL TRIALS
Registration: http://www.PBSS.org
Registration deadline:2018-08-01 (it will close sooner if the seating cap is reached)

About the Topic

In the wake of the BIA 10-2474 tragedy, in July 2017 the EMA updated their guideline on safety in first-in-human studies: "Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products." This sweeping new guideline suggests an evolving approach in Europe to patient safety in first-in-human studies, but it may reflect a changing global perspective as well. The guideline went into effect in February 2018, and its impacts on various aspects of early clinical trial design and execution are beginning to be realized. The full impacts of this guideline are still uncertain. Meanwhile, drug developers continue to prioritize patient safety by remaining scientifically focused while working to bring much-needed treatments expeditiously to patients with unmet medical needs.

About the Speakers

Dr. Michael Rothenberg has been at Genentech since January 2015 and is a Safety Science Medical Director in Early Development Safety, where he supports several molecule teams in early clinical development. Dr. Rothenberg received his MD PhD (Biochemistry) from UCSF in 2005 and then moved to Stanford University where he completed a residency and fellowship (Internal Medicine, Gastroenterology & Hepatology) as well as a postdoctoral research fellowship (Regenerative Medicine & Stem Cell Biology). He remains on faculty at Stanford as an Adjunct Assistant Clinical Professor of Medicine. He is passionate about science and drug development. In his spare time, he enjoys spending time with his family, traveling, and open water (and pool) swimming.

Other Events of PBSS-San Francisco Bay:

2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus

2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies

2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals

2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices

2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)

2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices

2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics

2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6

2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies

2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices

2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA